Spinal injuries therapy (NEUROREG) - Histocell
Latest Information Update: 28 Aug 2020
Price :
$50 *
At a glance
- Originator Histocell
- Developer Histocell; Noray Bioinformatics
- Class Cell therapies; Diagnostic agents
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Spinal cord injuries
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Spinal-cord-injuries in Spain (Parenteral)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Spinal-cord-injuries(Diagnosis) in Spain (Parenteral)
- 15 Jul 2016 Preclinical trials in Spinal cord injuries (Diagnosis) in Spain (Parenteral)